SuperworthElanco Animal Health profit margin ELAN
Gross, operating and net profit as a share of revenue over the last twelve months, from 2017.
- Net margin, 12 months
- −4.0%
- Operating margin, 12 months
- 1.6%
- Net margin on a year earlier
- −13.6 pts
- Peer median
- 15.0%
Over the twelve months to Jun 30, 2026, Elanco Animal Health kept −4.0% of its revenue as net profit, with an operating margin of 1.6% and a gross margin of 55.4%.
Five years earlier its net margin was −16.0%.
The median for 10 large drugmakers of a similar size is 15.0%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −4.9% | 0.3% | 55.0% |
| FY2024 | 7.6% | 2.3% | 54.9% |
| FY2023 | −27.9% | −19.1% | 56.3% |
| FY2022 | −1.8% | 4.6% | 56.6% |
| FY2021 | −10.1% | −9.4% | 55.2% |
| FY2020 | −17.1% | −21.4% | 49.1% |
| FY2019 | 2.2% | 6.0% | 52.1% |
| FY2018 | 2.8% | 4.7% | 48.7% |
| FY2017 | −10.8% | −8.1% | 48.3% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −4.0% | −13.6 pts | 1.6% | |
| Q1 FY26 | −4.9% | −13.4 pts | 1.1% | |
| Q4 FY25 | −4.9% | −12.5 pts | 0.3% | |
| Q3 FY25 | 0.8% | −3.8 pts | 4.3% | |
| Q2 FY25 | 9.7% | +37.6 pts | 3.9% | |
| Q1 FY25 | 8.4% | +38.3 pts | 2.8% | |
| Q4 FY24 | 7.6% | +35.5 pts | 2.3% | |
| Q3 FY24 | 4.6% | +30.8 pts | 1.7% | |
| Q2 FY24 | −27.9% | −25.3 pts | −20.5% | |
| Q1 FY24 | −29.8% | −29.2 pts | −21.5% | |
| Q4 FY23 | −27.9% | −26.1 pts | −19.1% | |
| Q3 FY23 | −26.2% | −23.4 pts | −18.8% |
Against its peers
Companies in Drug Manufacturers - General nearest Elanco Animal Health's size, closest first, today.
| Company | Profit margin |
|---|---|
| ELANElanco Animal Health | −4.0% |
| BMRNBiomarin Pharmaceutical | 2.1% |
| CORTCorcept Therapeutics | 6.6% |
| JAZZJazz Pharmaceuticals | 20.4% |
| PTGXProtagonist Therapeutics | 29.4% |
| TGTXTG Therapeutics | 55.2% |
| ALKSAlkermes plc. | 4.0% |
| AMRXAmneal Pharmaceuticals | 5.0% |
| LGNDLigand Pharmaceuticals | 67.9% |
| KNSAKiniksa Pharmaceuticals International | 9.6% |
| INDVIndivior Pharmaceuticals | 26.7% |
| Peer median | 15.0% |
Where Elanco Animal Health ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Elanco Animal Health
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.